26 January 2025 : Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Antibody Titers
Yoichiro Nakajima
1ABCDEF, Nahoko Kato-Kogoe 1ABCDEF*, Takako Yasuda2ABC, Rika Urakawa2BC, Tomoka Matsuo1DF, Michi Omori1BDF, Takaaki Ueno1ADEF, Tohru Takeuchi3ADE
DOI: 10.12659/MSM.947146
Med Sci Monit 2025; 31:e947146
Table 2 Rheumatoid arthritis parameters at baseline and at 3, 6, 9, and 12 months in each group with different timings of periodontal therapy initiation.
| Parameter | Group | Baseline | 3 months | 6 months | 9 months | 12 months |
|---|---|---|---|---|---|---|
| DAS28-CRP | A | 3.57(3.20–3.84) | 2.11(1.69–2.22)* | 1.52(1.27–2.24)* | 1.60(1.20–3.09) | 1.41(1.21–2.15)* |
| B | 3.67(2.96–4.99) | 3.16(2.10–3.91)* | 2.22(1.70–2.84)* | 2.04(1.54–2.16)* | 1.90(1.52–2.24)* | |
| C | 2.58(1.95–3.63) | 2.24(2.12–2.78) | 2.28(1.43–3.08) | 2.27(1.55–2.98) | 2.37(1.63–2.75) | |
| DAS28-ESR | A | 4.16(3.99–4.35) | 2.45(2.17–3.29)* | 2.30(1.91–2.79)* | 2.09(1.90–2.96)* | 2.32(1.57–2.73)* |
| B | 4.37(2.95–5.58) | 3.62(2.35–4.50) | 2.65(1.99–3.28)* | 2.24(1.60–2.81)* | 2.25(1.73–3.00)* | |
| C | 2.93(2.32–4.18) | 2.64(2.21–3.11) | 2.92(2.14–3.67) | 2.47(2.00–3.35) | 2.57(1.81–3.11) | |
| SDAI | A | 13.39 | 6.13* | 3.55* | 1.94* | 1.87* |
| (12.87–22.90) | (3.80–8.10) | (0.19–6.19) | (0.34–6.94) | (0.35–6.17) | ||
| B | 18.13(11.22–30.39) | 14.17(6.66–19.01)* | 9.25(6.81–14.29)* | 6.52(4.15–8.91)* | 5.22(3.08–9.10)* | |
| C | 9.09(5.07–16.46) | 5.24(3.78–12.00) | 8.67(2.53–11.39) | 7.78(3.18–11.18) | 5.57(2.44–9.51) | |
| CDAI | A | 13.00(11.20–22.80) | 6.10(3.60–7.40)* | 3.45(0.05–6.15)* | 1.90(0.10–6.85)* | 1.70(0.25–6.10)* |
| B | 17.85(11.20–27.50) | 14.15(6.40–19.00)* | 9.05(6.80–14.20)* | 6.50(4.10–8.80)* | 5.20(2.90–8.70)* | |
| C | 9.00(5.00–15.20) | 5.10(2.30–11.90) | 8.60(2.40–11.30) | 7.70(3.10–11.10) | 4.60(2.40–9.50) | |
| USGS28 Score | A | 19(11–22) | 15(8–21) | 9(6–11) | 6(0–15) | 11(8–14) |
| B | 21(13–48) | 16(12–38) | 19(14–22) | 15(12–24) | 15(6–19) | |
| C | 11(6–16) | 11(8–14) | 15(8–20) | 14(6–15) | 9(4–15) | |
| USPD28 Score | A | 10(5–12) | 6(3–11) | 1(1–6) | 2(0–3) | 1(0–3)* |
| B | 12(6–22) | 8(4–26) | 6(3–12)* | 4(2–7)* | 2(0–4)* | |
| C | 3(1–9) | 2(1–5) | 3(0–6) | 2(0–4) | 2(0–7) | |
| All values are expressed as median (interquartile range). DAS28-CRP – disease activity score including 28 joints using C-reactive protein; DAS28-ESR – disease activity score including 28 joints using erythrocyte sedimentation rate; SDAI – Simplified Disease Activity Index; CDAI – Clinical Disease Activity Index’; USGS – ultrasonographic using grayscale modes; USPD – ultrasonographic using power Doppler modes. * | ||||||